文献速递腹部CT

光子计数CT胰腺实质期显示胰腺导管腺癌的最佳虚拟单能量图像

Optimal virtual monoenergy for the detection of pancreatic adenocarcinoma during the pancreatic parenchymal phase on photon counting CT.
PubMed 文献 · Abdom Radiol (NY) · 2025-01-07

回顾性纳入54例胰腺实质期光子计数CT数据,定量分析40–120 keV虚拟单能量图像,并对40、55、70、85 keV行定性评估。40 keV胰腺实质对比噪声比及腺癌与实质衰减差最高但噪声最大;55 keV与40 keV腺癌显示评分无显著差异且整体图像质量更优、噪声更低。作者认为55 keV为胰腺评估及腺癌显示的最佳虚拟单能量。

要点

  • 胰腺实质期光子计数CT中55 keV虚拟单能量图像在腺癌显示与整体图像质量间取得最佳平衡。
  • 40 keV腺癌显示评分与55 keV无显著差异,但噪声更高、整体图像质量更低。
  • 70 keV整体图像质量最佳且噪声低于40和55 keV,但腺癌显示评分不及40和55 keV。

核心结论

  • 55 keV胰腺实质期虚拟单能量图像在光子计数CT上为胰腺评估及胰腺导管腺癌显示提供最佳综合表现,常规浏览55 keV图像可能改善腺癌检出。

研究设计与样本

  • 回顾性研究,经PACS检索连续纳入54例有胰腺实质期光子计数CT源数据的患者(28/54为男性,平均[SD]年龄62[13]岁),定量分析40–120 keV(每10 keV递增)虚拟单能量图像,并据定量结果与厂商建议选取40、55、70、85 keV由3名放射科医师盲法定性评估。

诊断标准与关键数值

  • 定量:40 keV胰腺实质CNR及腺癌与胰腺实质间衰减差最高,但噪声(HUsd)也最高;定性(5分Likert):70 keV整体图像质量最佳(均值[SE] 3.7[0.1]),噪声低于40和55 keV(3.6[0.08] vs 1.8[0.07]和2.7[0.05],p < .001);40 keV胰腺强化最强(4.6[0.11]);腺癌显示评分40 keV与55 keV最高且两者无显著差异(4.4[0.13]和4.3[0.14],Tukey adj-p = .20);55 keV整体图像质量高于40 keV(3.4[0.08] vs 2.5[0.08],Tukey adj-p < .001)、噪声低于40 keV(2.7[0.05] vs 1.8[0.07],Tukey adj-p < .001)。

临床应用与阅片要点

  • 作者认为常规浏览光子计数CT胰腺实质期55 keV虚拟单能量图像可能改善胰腺导管腺癌检出;40 keV腺癌显示与55 keV无显著差异但噪声更高、整体图像质量更低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: As the pancreas is a low contrast visibility organ, pancreatic ductal adenocarcinoma detection is challenging due to subtle attenuation differences between tumor and pancreatic parenchyma. Photon counting CT (PCCT) has superior iodine contrast-to-noise ratio than conventional CT and also affords the creation of low keV virtual monoenergetic images, both of which increase adenocarcinoma conspicuity. The purpose therefore was to identify the optimal virtual monoenergy for visualizing PDAC during the pancreatic parenchymal phase of enhancement at PCCT using both quantitative and qualitative analyses.

METHODS: Consecutive patients with pancreatic parenchymal phase PCCT source data were retrospectively identified by PACS search. For the quantitative analysis, region of interest (ROI) measurements were drawn in the pancreatic head, body, tail, pancreatic adenocarcinoma (if present), and psoas muscles on 40-120 keV virtual monoenergetic images in 10 keV increments. Based on the quantitative analysis results and vendor recommendations, four virtual monoenergies(40 keV, 55 keV, 70 keV, and 85 keV) were selected for additional qualitative analysis. Three radiologists blinded to four virtual monoenergies assessed overall image quality, image noise, pancreatic enhancement, and pancreatic mass conspicuity on 5-point Likert scales.

RESULTS: 54 patients (28/54 male, mean[SD] age: 62 [13] years) were included. Quantitatively, 40 keV had the highest pancreatic parenchymal CNR and attenuation difference between the adenocarcinoma and parenchyma, but also the highest noise (HUsd). Qualitatively, 70 keV had the best overall image quality (Mean [SE]: 3.7[0.1]) and lower noise than 40 and 55 keV (3.6[0.08] vs. 1.8[0.07] and 2.7[0.05], respectively, p < .001). 40 keV had the greatest pancreatic enhancement (mean[SE] 4.6[0.11]). Adenocarcinoma conspicuity ratings were greatest at 40 keV and 55 keV, and not significantly different from each other (mean[SE] 4.4[0.13] and 4.3[0.14], respectively, Tukey adj-p =.20). 55 keV had greater overall image quality and lower noise than 40 keV (mean[SE] 3.4[0.08] vs. 2.5[0.08], Tukey adj-p < .001 and 2.7[0.05] vs. 1.8[0.07], Tukey adj-p < .001 respectively).

CONCLUSION: 55 keV pancreatic parenchymal phase virtual monoenergetic images afford optimal pancreatic assessment at PCCT for the visualization of pancreatic adenocarcinoma. Routinely viewing 55 keV virtual monoenergetic images at PCCT may improve PDAC detection.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Ruff A, Li X, Goldberg JD, et al. Optimal virtual monoenergy for the detection of pancreatic adenocarcinoma during the pancreatic parenchymal phase on photon counting CT. Abdom Radiol (NY). 2025. PMID: 39775026. doi:10.1007/s00261-024-04696-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。